Cardiol Therapeutics Inc.
CRDL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -179.9% |
| R&D Expenses | $14 | $11 | $14 | $9 |
| G&A Expenses | $26 | $0 | $0 | $0 |
| SG&A Expenses | $26 | $12 | $16 | $22 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $40 | $22 | $30 | $30 |
| Operating Income | -$40 | -$22 | -$30 | -$31 |
| % Margin | – | – | – | -49,092.4% |
| Other Income/Exp. Net | $4 | $1 | $8 | $6 |
| Pre-Tax Income | -$37 | -$21 | -$23 | -$25 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$37 | -$21 | -$23 | -$25 |
| % Margin | – | – | – | -40,170.9% |
| EPS | -0.51 | -0.44 | -0.49 | -0.73 |
| % Growth | -15.9% | 10.2% | 32.9% | – |
| EPS Diluted | -0.51 | -0.44 | -0.49 | -0.73 |
| Weighted Avg Shares Out | 72 | 64 | 63 | 43 |
| Weighted Avg Shares Out Dil | 72 | 64 | 63 | 43 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $2 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$40 | -$21 | -$23 | -$25 |
| % Margin | – | – | – | -39,891% |